Skip to content

Research on the enhancement of sedation effects of sufentanil combined with propofol

Research on the enhancement of sedation effects of sufentanil combined with propofol

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108592
Enrollment
Unknown
Registered
2025-09-02
Start date
2025-10-21
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

CIP-Su Group:Administered cipepofol via intravenous injection at a rate of 10 mg/kg/h
Su-CIP Group:Administered sufentanyil (0.4 µg/kg) via intravenous injection

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65 years, classified as ASA I-III, scheduled for elective surgery under general anesthesia, with postoperative recovery planned in the recovery room.

Exclusion criteria

Exclusion criteria: 1. Patients with difficult airway; 2. Those who are allergic or abuse of opioids; 3. Patients with severe hypertension; 4. Patients with severe arrhythmias; 5. Patients with severe cardiac insufficiency; 6. Patients with liver and kidney dysfunction; 7. Pathological obesity; 8. Women in labor, childbirth or lactation; 9. Patients whose preoperative state of consciousness is difficult to determine independently or accurately; 10. Patients with a history of psychotropic drug use; 11. Patients with myasthenia gravis.

Design outcomes

Primary

MeasureTime frame
Duration of loss of consciousness and BIS <= 60 following remimazolam injection.;

Secondary

MeasureTime frame
vital signs;Characteristics of anesthesia and surgery;Patient Comfort Assessment;

Countries

People’s Republic of China

Contacts

Public ContactGuan Xuehai

The First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 185 8769 7310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026